Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.46 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25203439 | 1.00 | HTR2C (0.52) | HTR2CPRMT5HTR2AHRH3CYP2D6 | |
| SCHEMBL25208253 | 0.85 | HTR2C (0.50) | HTR2CPRMT5HTR2AHRH3CYP2D6 | |
| SCHEMBL25200967 | 0.85 | HTR2C (0.50) | HTR2CPRMT5HTR2AHRH3CYP2D6 | |
| SCHEMBL30839291 | 0.83 | HTR2C (0.73) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| SCHEMBL25521336 | 0.83 | HTR2C (0.73) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| SCHEMBL29162348 | 0.83 | HTR2C (0.73) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| SCHEMBL32687914 | 0.82 | HTR2C (0.45) | HTR2CPRMT5HTR2AHRH3CYP2D6 | |
| SCHEMBL25266654 | 0.81 | HTR2C (0.46) | HTR2CPRMT5HTR2AHRH3CYP2D6 | |
| SCHEMBL25206817 | 0.81 | HTR2C (0.46) | HTR2CPRMT5HTR2AHRH3CYP2D6 | |
| SCHEMBL25423999 | 0.74 | MEN1 (0.51) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC. | 2026-03-19 | — | — | US | disclosed |
| EP-4423060-A2 | PSYCHOPLASTOGENIC N-SUBSTITUTED INDOLES | Terran Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023077127-A2 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023077127-A2 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, TPH1, HTR3D | HTR2C 5/4885PRMT5 575/4885HTR2A 13/4885 |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, HTR2C, TPH1 | HTR2C 2/4885PRMT5 946/4885HTR2A 14/4885 |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TPH2, TPH1, AANAT | HTR2C 11/4885PRMT5 661/4885HTR2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.